Bristol Myers Squibb

News

Cytokinetics rockets on positive heart drug trial

Shares in US biotech Cytokinetics have popped after a report that its aficamten drug improved symptoms in people with a rare and progressive form of heart disease.

News

BMS strikes again, with $4.1bn RayzeBio takeover bid

Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal i

News

BMS wagers $14bn on Karuna’s schizophrenia drug

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approxim

News

BMS’ LAG-3 RELATIVITY theory fails futility test

Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after

News

BMS bolts on SystImmune bispecific ADC in $8.4bn deal

The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending.

News

BMS chases MSD/Seagen with first-line bladder cancer filing

The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting

Cytokinetics rockets on positive heart drug trial

BMS strikes again, with $4.1bn RayzeBio takeover bid

BMS wagers $14bn on Karuna’s schizophrenia drug

BMS’ LAG-3 RELATIVITY theory fails futility test

BMS bolts on SystImmune bispecific ADC in $8.4bn deal

BMS chases MSD/Seagen with first-line bladder cancer filing

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks